Search Bar & Filters
Found 27 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of two types of free gingival graft surgeriesconventional free gingival graft FGG and modified free gingival graft ModFGGon soft tissue thickness, volume, and creeping attachment in the lower front teeth. This trial involves 34 healthy, non-smoking adults with localized Cairo Class II gingival recession. The goal is to understand how the modified technique may improve soft tissue stability and volume compared to the conventional method, using advanced three-dimensional digital analysis. Participants will be randomly assigned to receive either the conventional FGG procedure or the modified ModFGG procedure. The ModFGG involves creating a connective tissue flap from the recession area to cover the exposed root before placing a graft from the palate, aiming to enhance blood supply and healing. The conventional FGG involves placing a graft from the palate directly onto the prepared site without this flap. Both procedures will be followed by digital and clinical assessments at baseline, and at 1, 3, and 6 months after surgery. During the study, participants will undergo clinical measurements including gingival recession depth, keratinized tissue width, and probing depth, alongside three-dimensional digital scans with an intraoral scanner to evaluate soft tissue thickness and volume changes. These evaluations at multiple time points will help assess tissue stability and healing progress. The study will last at least six months post-surgery, providing detailed information on soft tissue outcomes and healing after these grafting procedures.
Actively Recruiting
Researchers are investigating the frequency of Neuronal Ceroid Lipofusinosis Type 2 CLN2 in children aged 2 to 6 years who have nonspecific neurological symptoms such as idiopathic seizures, speech disorders, and motor dysfunctions. This multicenter, non-drug screening study focuses on children without hypoxic ischemic encephalopathy, head trauma, or developmental brain anomalies, aiming to better understand the demographic and clinical features of those with possible CLN2 disease. Children first undergo assessments including recording demographic and medical history, seizure frequency, cognitive and language development evaluations, physical exams assessing muscle strength, gait, and coordination, as well as neurological evaluations using EEG and MRI scans. Those showing specific signs like speech disorder with seizures, movement problems, particular EEG responses, or MRI findings will have blood samples taken to measure Tripeptidyl Peptidase 1 enzyme levels. If enzyme activity is low, genetic testing is performed to investigate CLN2 disease. Participants are involved for up to one year during which various clinical, neurological, and imaging evaluations are done. Blood samples are collected for enzyme and genetic analyses. The main outcome measured is the frequency of CLN2 disease in this group. The study tracks each childs symptoms, neurological findings, and imaging results to better identify and understand CLN2 in children with these symptoms.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of AZD4144 in adults aged 18 to 80 years with sepsis-associated acute kidney injury. This Phase IIa, randomized, double-blind, placebo-controlled study includes participants who have sepsis caused by suspected or confirmed bacterial infection requiring vasopressor or inotrope treatment and developed acute kidney injury within 72 hours of sepsis onset. Participants will be randomly assigned to receive either intravenous AZD4144 or a matching placebo once daily for a fixed treatment period. During this time, daily safety monitoring and collection of blood and urine samples will occur. After treatment, participants will continue to be monitored daily while hospitalized and will have up to two follow-up visits after discharge to assess safety and kidney function. Throughout the study, researchers will measure kidney function markers such as 24-hour creatinine clearance and other related outcomes. Additional assessments include monitoring days alive without kidney replacement therapy, mechanical ventilation, or hospitalization over approximately 30 days. Safety and tolerability will be closely observed during and after treatment, with the total participation spanning screening, treatment, hospitalization monitoring, and post-discharge follow-up visits.
Actively Recruiting
This research focuses on young earthquake survivors aged 20 to 25 to understand the long-term risk of trauma-induced stress. It evaluates how non-invasive sound therapy affects the vagal nerve by monitoring cardiovascular and neural activity. The study aims to explore biofeedback methods that could help manage stress-related responses in these individuals, considering the psychological and physical impacts of trauma such as wars and natural disasters. Participants will be divided into three groups one group receives no stimulation during mental stress, another undergoes phonocardiographic PCG auditory stimulation, and the third group receives metronome-like stimulation matching the heart rhythm MHR. These interventions are applied during mental stress to assess their effect on stabilizing the autonomic nervous system. The study uses advanced data processing methods like deep learning to analyze biological signals collected during these interventions. During the study, various biological signals will be recorded, including electrocardiography ECG, phonocardiography PCG, electrodermal activity, respiratory rhythm, and near-infrared spectroscopic imaging fNIRS. Participants emotional and psychological states will be evaluated through these signals at baseline and throughout the 2-month study period. Researchers will monitor cardiovascular and neuro-cardiac responses to assess biofeedback effects and stress coping. The total study duration includes baseline measures and follow-up assessments over two months.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Advances in neonatal care have improved survival rates for very low birth weight infants but have led to increased rates of conditions such as cerebral palsy, cardiorespiratory disorders, blindness, cognitive delays, and hearing impairments. Early diagnosis and intervention programs in neonatal intensive care units NICU aim to support the development of these at-risk infants by normalizing their motor, cognitive, and sensory skills. This study focuses on evaluating the effects of early family-involved physiotherapy on motor development in infants at risk after NICU discharge, using tools like Prechtls General Movements Assessment and the Motor Optimality Score - Revised MOS-R. Participants will be randomly assigned to either an early physiotherapy program or a control group. The intervention group will receive a tailored family collaborative physiotherapy program including education on handling, carrying, positioning, and sucking facilitation to stimulate postural responses, integrated into daily routines. The control group will receive routine developmental NICU care plus a one-time instruction on positioning and carrying at discharge. The program continues with family recommendations until the infant reaches the studys evaluation points. Participants will be assessed for motor skills using the Motor Optimality Score and Prechtls General Movements Assessment between 12 and 20 weeks postterm. Additional evaluations include neurological exams Hammersmith Neonatal and Infant Neurological Examinations and cognitive and language development assessments BAYLEY-III at 3 and 6 months corrected age. Sociodemographic data will be collected at baseline. The study aims to measure the impact of early physiotherapy on neurological and developmental outcomes in at-risk infants within a 4-month age range.
1-10 of 27
1